{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:50Z","timestamp":1790207750399,"version":"4.1.0"},"reference-count":21,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: In September 2021, pemigatinib received Health Canada approval for previously treated locally advanced\/metastatic cholangiocarcinoma (CCA) with FGFR2 rearrangements\/fusions. This retrospective study aimed to characterize the real-world management and outcomes of patients with CCA receiving pemigatinib through a Canadian patient support program (PSP). Methods: We evaluated a multi-centre case series of Canadian patients who were prescribed pemigatinib between September 2021 and January 2023 for eligible CCA diagnoses and enrolled in the PSP. The retrospective study data included demographic and disease-, treatment-, and outcome-related information, and these were collected using a survey of prescribing physicians. Results: Of the 26 patients who initiated pemigatinib in the PSP, we received survey responses for 18 (69%). Their median age was 57 years, 67% were female, 61% had stage IV disease, and 83% had intrahepatic CCA. Prior to pemigatinib, a partial hepatectomy was performed in 44% of the patients, and 66% of the patients received 2\u20134 prior lines of systemic therapy. All patients were treated with platinum-based regimens as the first-line treatment for unresectable\/metastatic disease. The median follow-up time on pemigatinib was 12.6 (range: 2.3\u201328.4) months, and their median real-world progression-free survival (rwPFS) was 12.1 months (95% CI 7.2-NR). The physician-assessed objective response and disease control rates were 56% and 89%, respectively. For the nine patients who discontinued pemigatinib, the median treatment duration was 10.6 months (range: 0.8\u201321.7). Disease progression was the most common reason for discontinuation (89%). None discontinued due to adverse events. Conclusions: Objective response rates, disease control rates, and a PFS comparable to that in the phase 2 FIGHT-202 trial was reported with pemigatinib use in this Canadian PSP cohort.<\/jats:p>","DOI":"10.3390\/curroncol32070405","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T10:46:05Z","timestamp":1752662765000},"page":"405","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0413-5485","authenticated-orcid":false,"given":"Philip Q.","family":"Ding","sequence":"first","affiliation":[{"name":"Oncology Outcomes Research Program, University of Calgary, Calgary, AB T2N 4N1, Canada"},{"name":"Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Tam","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, University of Calgary, Calgary, AB T2N 5G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-3505","authenticated-orcid":false,"given":"Ravi","family":"Ramjeesingh","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Nova Scotia Health, Dalhousie University, Halifax, NS B3H 2Y9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Asselah","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Sheffield","sequence":"additional","affiliation":[{"name":"Division of Advanced Diagnostics, William Osler Health System, Brampton, ON L6R 3J7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Incyte Biosciences Canada, Pointe-Claire, QC H9R 0A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Julie","family":"Gaudreau","sequence":"additional","affiliation":[{"name":"Incyte Biosciences Canada, Pointe-Claire, QC H9R 0A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, UHN Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Oncology Outcomes Research Program, University of Calgary, Calgary, AB T2N 4N1, Canada"},{"name":"Division of Medical Oncology, Department of Oncology, University of Calgary, Calgary, AB T2N 5G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: Current knowledge and new developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102170","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1477-3163.151940","article-title":"Cancer review: Cholangiocarcinoma","volume":"14","author":"Ghouri","year":"2015","journal-title":"J. Carcinog."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1758835920953293","DOI":"10.1177\/1758835920953293","article-title":"FGFR inhibitors in cholangiocarcinoma: What\u2019s now and what\u2019s next?","volume":"12","author":"Saborowski","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10732748231211764","DOI":"10.1177\/10732748231211764","article-title":"Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States from 2000 to 2018","volume":"30","author":"Nghiem","year":"2023","journal-title":"Cancer Control."},{"key":"ref_7","unstructured":"National Comprehensive Cancer Network (2024). Biliary Tract Cancers, NCCN. version 3.2024."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.3390\/curroncol30080517","article-title":"A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada","volume":"30","author":"Ramjeesingh","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103488","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: Final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"key":"ref_14","unstructured":"Government of Canada (2021). Summary Basis of Decision\u2014Pemazyre\u2014Health Canada, Available online: https:\/\/hpr-rps.hres.ca\/reg-content\/summary-basis-decision-detailTwo.php?linkID=SBD00576&lang=en."},{"key":"ref_15","unstructured":"Qualtrics XM Provo, UT: Qualtrics. Available online: https:\/\/www.qualtrics.com."},{"key":"ref_16","unstructured":"R Core Team (2023). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.2024.42.3_suppl.444","article-title":"Real-world (RW) characteristics, treatment patterns, and outcomes of patients with cholangiocarcinoma (CCA) treated with pemigatinib","volume":"42","author":"Saverno","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"113587","DOI":"10.1016\/j.ejca.2024.113587","article-title":"Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies","volume":"200","author":"Saverno","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_19","unstructured":"Institut national d\u2019excellence en sant\u00e9 et en services sociaux (2023). PEMAZYRE (Cholangiocarcinome) Avis Transmis au Ministre en Octobre 2023, INESSS."},{"key":"ref_20","unstructured":"Tam, V., Tang, P., and Tilley, D. (2023). Clinical Practice Guideline on Cholangiocarcinoma and Gallbladder Cancer, Cancer Care Alberta, Alberta Health Services. version 6."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Canada\u2019s Drug Agency (CDA-AMC) (2025). Reimbursement Recommendation Pemigatinib (Pemazyre). Can. J. Health Technol., 5, 5.","DOI":"10.51731\/cjht.2025.1132"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/405\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:34Z","timestamp":1760033434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["curroncol32070405"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32070405","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}